Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.

Panagiotis Andreadis Thomas Karagiannis Konstantinos Malandris Ioannis Avgerinos Aris Liakos Apostolos Manolopoulos Apostolos Tsapas David R Matthews Apostolos Tsapas

Published in: Diabetes, obesity & metabolism (2018)

Semaglutide is a potent once-weekly GLP-1 RA, significantly reducing HbA1c, body weight and systolic blood pressure. However, it is associated with increased incidence of gastrointestinal adverse events. Results for pancreatitis and retinopathy require further assessment in post-approval pharmacovigilance studies.

Keyphrases

body weight
blood pressure
hypertensive patients
heart rate
rheumatoid arthritis
risk factors
adverse drug
glycemic control
heart failure
left ventricular
case control
disease activity
anti inflammatory
drug administration
interstitial lung disease
cardiovascular disease